bluebird bio (BLUE) Price Target Reduced to $149 at BofA/Merrill Lynch
Tweet
Share
E-mailGet Alerts BLUE Hot Sheet
Price: $4.97 --0%
Rating Summary:
10 Buy, 19 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 4 | New: 14
Rating Summary:
10 Buy, 19 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 1 | Down: 4 | New: 14
Join SI Premium – FREE
BofA/Merrill Lynch maintained a Buy rating on bluebird bio (NASDAQ: BLUE) but lowered its price target to $149.00 (from $241.00). Analyst Ying Huang reduced the addressable market for BB305 to 50% in severe thalassemia patients ineligible for stem cell transplant and lowered approval probability to 42% following recent data.
For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.
Shares of bluebird bio closed at $70.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Tata Technologies (TATATECH:IN) to Underweight
- Alimentation Couche-Tard Inc (ATD/B:CN) (ANCUF) PT Raised to Cdn$104 at UBS
- JPMorgan Downgrades Wipro Ltd. (WPRO:IN) (WIT) to Underweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
